



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

13th May 2024

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: 531569

ISIN: INE860D01013

Subject: Press Release

We enclose herewith a Press Release issued by the Company on Un-Audited Financial Results for the quarter ended June 30, 2024.

Please take same on your record.

Thanking You,

Yours faithfully,
For Sanjivani Paranteral Ltd.

Pritesh Jain
Chief Financial Officer

Encl: As Above

Press Release

Sanjivani Paranteral Limited reported a strong performance for the quarter ended 30th June 2024

Mumbai, 6th August 2024: Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said, "We are pleased to report a strong performance for Q1 FY 2025, reflecting our commitment towards high-quality pharmaceutical products. Our oral product segment showed exceptional performance, and the injectables segment showed consistent results this quarter. However, we remain confident in our long-term strategy and continue to invest in innovation and R&D. Our focus on export markets has also proven fruitful, contributing significantly to our overall revenue. Despite the challenges posed by a dynamic global environment, our diversified portfolio and strategic focus have enabled us to achieve a significant year-over-year revenue growth."

Financial Summary:

Q1 FY25:

- Revenue from operation grew 31% YoY to Rs. 165mn.
- EBITDA margin stood at 14.7%.
- Profit After Tax (PAT) up 11% at 17mn.

Segment-wise Performance:

- **Injectables:** Revenue de-grew 4.6% YoY to Rs. 61.1mn.
- **Oral:** Revenue grew 116.6% YoY to Rs. 99.3mn.
- **Nutraceuticals:** Revenue grew 61.3% YoY to Rs. 4.0mn.

Market-Wise Performance:

- Exports (incl. Exports incentives) constitutes 87.2% of total revenue while domestic constitutes the rest.
- Core markets of CIS (incl Russia), Middle east & Africa and Latin America, accounted for 88.2% to Rs. 145.04mn.

Pritesh Jain

Sanjivani Paranteral
Chief Financial Officer
pritesh.jain@sanjivani.co.in

Vijay Gyanchandani / Jill Chandrani

S-ancial Technologies
vijay@s-ancial.com / jill@s-ancial.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.